Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply

Abstract:
NANOBIOTIX (Euronext: NANO-ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced the appointment of Thierry Otin as Head of Manufacturing and Supply. The appointment strengthens the Nanobiotix organisation, Mr Otin will be responsible for the manufacturing plans to move the lead product, NBTXR3, from clinical trials into full commercialization as from 2016.

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply

Paris, France | Posted on April 15th, 2014

Prior to joining Nanobiotix, Mr Otin was the Quality Site Manager (EU Sterile) at Roche and before then, he worked at LFB Biotechnologies as the Head Pharmacist (Pharmaceutical Qualified Person) and Quality Director. Prior to this, he worked in QA/GMP and manufacturing with world class companies including, Schering CISBiointernational, Institut de Formation des Industries de Santé (IFIS), UCB, Delagrange and Rhône-Poulenc (Roger Bellon and Specia). He has a degree in biology and has a doctorate in Pharmacy from the University of Strasbourg.

Laurent Levy, CEO of Nanobiotix said: "Thierry Otin joins us having had over 30 years' experience in the global pharmaceutical industry which includes 12+ years' experience of injectable drug production management and 11+ years in QA senior compliance management. This wealth of expertise will be invaluable to us as we move our lead product to commercialization. We welcome him to the team."

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

For more information, please click here

Contacts:
Sarah Gaubert
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55


Media Relations
France - NewCap
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)6 88 20 35 59
/

Financial communication and investors relations
NewCap.
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53


Instinctif Partners
Melanie Toyne Sewell / Katherine Lynch / Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists join forces to reveal the mass and shape of single molecules April 27th, 2015

The 16th Trends in Nanotechnology International Conference (TNT 2015) unveils 25 Keynote Speakers: Call for abstracts open April 27th, 2015

Graphenea celebrates fifth anniversary April 27th, 2015

Sensor Designed in Iran Able to Remove Formaldehyde Gas from Environment April 27th, 2015

Nanomedicine

Scientists join forces to reveal the mass and shape of single molecules April 27th, 2015

Northwestern scientists develop first liquid nanolaser: Technology could lead to new way of doing 'lab on a chip' medical diagnostics April 25th, 2015

Nanotech-enabled moisturizer speeds healing of diabetic skin wounds: Spherical nucleic acids silence gene that interferes with wound healing April 24th, 2015

Fast and accurate 3-D imaging technique to track optically trapped particles April 24th, 2015

Announcements

Scientists join forces to reveal the mass and shape of single molecules April 27th, 2015

The 16th Trends in Nanotechnology International Conference (TNT 2015) unveils 25 Keynote Speakers: Call for abstracts open April 27th, 2015

Graphenea celebrates fifth anniversary April 27th, 2015

Sensor Designed in Iran Able to Remove Formaldehyde Gas from Environment April 27th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015

Nanofilm Appoints Senior Sales/Marketing Executives: Don Tecco, Director of Optical Sales, North America and Rex Talbott, Business Director Optical Products March 23rd, 2015

KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project